Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats

European Journal of Pharmaceutical Sciences

Volumn 46, Issue 1-2, 2012, Pages 32-42

  Gandhi, Sonia ^a   Srinivasan, B P ^a   Akarte, Atul Sureshrao ^a  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

Author keywords

Antifibrotic; Antiproteinuric; Glomerular filtration rate; Glucose homeostasis; RAAS

Indexed keywords

ADIPONECTIN; ALBUMIN; ALISKIREN; BETA 2 MICROGLOBULIN; CREATININE; CYSTATIN C; ERYTHROPOIETIN; GLUCOSE; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; NITRIC OXIDE; OLMESARTAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; GENE TRANSLOCATION; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG THERAPY, COMBINATION; FUMARATES; GLOMERULAR FILTRATION RATE; GLUCOSE TRANSPORTER TYPE 2; GLUCOSE TRANSPORTER TYPE 4; HUMANS; IMIDAZOLES; INSULIN; KIDNEY; LIVER; MUSCLE, SKELETAL; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; SERUM ALBUMIN; TETRAZOLES; TIME FACTORS;

EID: 84859212040     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.02.002     Document Type: Article

References (69)

1. Anderson, S., 1997. Role of local and systemic angiotensin in diabetic renal disease. Kid. Intl. 52 (63), S107-S110. (Pubitemid 28020446)
2. Atkins, R.C., Briganti, E.M., Lewis, J.B., Hunsicker, L.G., Braden, G., 2005. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am. J. Kid. Dis. 45, 281-287. (Pubitemid 40431053)
3. Azizi, M., Menard, J., Bissery, A., Guyenne, T.T., Bura-Rivière, A., Vaidyanathan, S., Camisasca, R.P., 2004. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. 15 (12), 3126-3133. (Pubitemid 39578845)
4. Birkenhäger, W.H., Staessen, J.A., 2007. Dual inhibition of the renin system by aliskiren and valsartan. www.thelancet.com. 370(9583), 195-196.
5. Brenner, B.M., 1983. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kid Intl. 23, 647-655. (Pubitemid 13135663)
6. Byung, W.L., Sung, H.I., Moon, G.C., Hyung, J.Y., 2007. The comparison of cystatin C and creatinine as an accurate serum marker in the prediction of type 2 diabetic nephropathy. Diabetes Res. Clin. Pract. 78, 428-434.
7. Casadevall, N., 1995. Cellular mechanism of resistance to erythropoietin. Nephrol. Dial. Transplant. 6, 27-30.
8. Chen, H., Qing, L.I., Yu-qian, B.A.O., Jun-ling, T., Hui-juan, L.U., Kun-san, X., Wei-ping, J., 2009. The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression. Acta. Pharmacol. Sinica. 30 (2), 242-250.
9. Cohen, N.C., 2007. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. Chem. Biol. Drug Des. 70, 557-565.
10. Craig, C and Stitzel, R.E., 2003. Modern Pharmacology with Clinical Applications. Fifth Edition: 156, 213, 217
11. Daniel, J.R., 1991. β-cell in type 2diabetes mellitus. Diabetes 40, 116-180.
12. David, J., 2005. Evaluation of renal function. Nephrology 10, 133-176.
13. De Jong, P.E., Navis, G.J., De Zeeuw, D., 1999. Renoprotective therapy: titration against urinary protein excretion. Lancet 354, 352-353. (Pubitemid 29355744)
14. de Zeeuw, D., Remuzzi, G., Parving, H.H., Keane, W.F., Zhang, Z., Shahinfar, S., 2004a. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from renal. Kid. Intl. 65, 2309-2320. (Pubitemid 38670018)
15. de Zeeuw, D., Remuzzi, G., Parving, H.H., Keane, W.F., Zhang, Z., Shahinfar, S., 2004b. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921-927. (Pubitemid 39128617)
16. Eijkelkamp, W.B., Zhang, Z., Remuzzi, G., Parving, H.H., Cooper, M.E., Keane, W.F., 2007. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 18, 1540-1546. (Pubitemid 46717521)
17. Filler, G., Witt, I., Priem, F., Ehrich, J.H.H., Jung, K., 1997. Are cystatin Cand b2- microglobulin better markers than serum creatinine for prediction of a normal glomerular filtration rate in pediatric subjects? Clin. Chem. 43 (6), 1997.
18. Fisher, J.W., 2003. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 228, 1-14. (Pubitemid 36077622)
19. Fossa, A.A., De Pasquale, M.J., Ringer, L.J., Winslow, R.L., 1994. Synergistic effect onreduction in blood pressure with coadministration of a renin inhibitor or an angiotensin-converting enzyme inhibitor with an angiotensin II receptor antagonist. Drug Dev. Res. 33, 422-428.
20. Gelman, L., Feige, J.N., Desvergne, B., 2007. Molecular basis of selective PPARc modulation for the treatment of Type 2 diabetes. Biochim. Biophys. Acta 1771, 1094-1107. (Pubitemid 47214561)
21. Grieve, K.A., Balazs, N., Comper, W.D., 2001. Protein fragments in urine have been considerably underestimated by various protein assays. Clin. Chem. 47, 1717-1719. (Pubitemid 32781594)
22. He, M., Zhang, L., Shao, Y., Wang, X., Huang, Y., Yao, T., Lu, L., 2009. Inhibition of renin /prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur. J. Pharmacol. 606, 155-161.
23. Huang, Y., Noble, N.A., Zhang, J., Xu, C., Border, W.A., 2007. Renin-stimulated TGFbeta1 expression isregulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 72, 45-52. (Pubitemid 47014443)
24. Huang, Y., Wongamorntham, S., Kasting, J., McQuillan, D., Owens, R.T., Yu, L., Noble, N.A., Border, W., 2006. Renin increases mesangial cell transforming growth factor-beta 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 69, 105-113. (Pubitemid 43117745)
25. Ingelfinger, J.R., 2008. Aliskiren and dual therapy in type 2 diabetes mellitus. N. Engl. J. Med. 358, 2503-2505. (Pubitemid 351793025)
26. Johnston, C.I., Risvanis, J., Naitoh, M., Tikkanen, I., 1998. Mechanism of progression of renal disease-current hemodynamic concepts. J Hypertens. 16, S3-S7. (Pubitemid 28482852)
27. Kaysen, G., Don, B.R., 2010. Serum albumin concentration and chronic kidney disease. US Nephrol. 5 (1), 20-27.
28. Kelly, D.J., Wilkinson-Berka, J.L., Allen, T.J., Cooper, M.E., Skinner, S.L., 1998. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kid. Int. 154, 343-352. (Pubitemid 28357396)
29. Kelly, D.J., Zhang, Y., Moe, G., Naik, G., Gilbert, G., 2007. Aliskiren, anovel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50, 2398-2404. (Pubitemid 47512400)
30. Kezama, J.J., Kutsuwada, K., Ataka, K., Maruyama, H., Gejyo, F., 2002. Serum cystatin Creliably detects renal dysfunction in patients with various renal diseases. Nephron 91, 13-20. (Pubitemid 34522827)
31. Kurien, B.T., Everds, N.E., Scofield, R.H., 2004. Experimental animal urine collection: a review. Lab. Anim. J. 38, 333-361. (Pubitemid 39350201)
32. Lakshmanan, A.P., Thandavarayan, R.A., Watanabe, K., Sari, F.R., Meilei, H., Giridharan, V.V., Sukumaran, V., Soetikno, V., Arumugam, S., Suzuk, K., Kodama, M., 2011. Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. Mol. Cell. Endocrin. doi:10.1016/j.mce.2011.07.041.
33. Lapsley, M.P.A., Sansom, C.T., Marlow, F.V., Norden, A.G.W., 1991. Beta2- glycoprotein- 1(apolipoprotein H) excretion in chronic renal tubular disorders: comparison with other protein markers of tubular malfunction. J. Clin. Pathol. 44, 12-816.
34. Macdougall, I.C., Cooper, A., 2002. The inflammatory response and epoetin sensitivity. Nephrol. Dial. Transplant. 17, 48-52. (Pubitemid 34157120)
35. Maillard, M.P., Würzner, G., Nussberger, J., Centeno, C., Burnier, M., Brunner, H.R.,2002. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin. Pharmacol. Ther. 71, 68-76. (Pubitemid 34124040)
36. Mann, D.L., Deswal, A., 2003. Angiotensin-receptor blockade in acute myocardial infarction-A matter of dose. N. Engl. J. Med. 349, 1963-1965. (Pubitemid 37409714)
37. María, L., Peñacarrillo, V., Puente, J., Redondo, A., Clemente, F., Valverd, I., 2001. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine 15 (2), 241-248. (Pubitemid 32977337)
38. Masiello, P., Broca, C., Gross, R., Roye, M., Manteghetti, M., Hillaire-Buys, D., Novelli, M., Ribes, G., 1998. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 47, 224-229. (Pubitemid 28079978)
39. Matsuno, T., Sasaki, H., Nakagawa, K., 1997. Fas antigen expression and apoptosis in kidney allografts. Transplant. Proc. 29, 177-178. (Pubitemid 27123365)
40. Morgan, T., Griffiths, C., Delbridge, L., 2002. Low doses of angiotensin converting enzyme inhibitors and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive. Am. J. Hypertens. 15, 1003-1005. (Pubitemid 35217409)
41. Morín, J.D.H., Málaga, S., Fernández, N., Rey, C., Diéguez, M.A., Solís, G., Concha, A., Medina, A., 2007. Cystatin Cand b2-microglobulin: markers of glomerular filtration in critically ill children. Crit. Care 11, R59.
42. Moriyama, T., Tsuruta, Y., Kojima, C., Itabashi, M., Sugiura, H., Takei, T., Ogawa, T., Uchida, K., Tsuchiya, K., Nitta, K., 2011. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int. Urol. Nephrol., doi:10.1007/s11255- 011-9991-0.
43. Nakamaki, S., Satoh, H., Kudoh, A., Hayashi, Y., Hirai, H., Watanabe, T., 2011. Adiponectin reduces proteinuria instreptozotocin-induced diabetic Wistar rats. Exp. Biol. Med. (Maywood) 236 (5), 614-620.
44. Nguyen, G., Burckle, C., Sraer, J.D., 2003. The renin receptor: the facts, the promise and the hope. Curr. Opin. Nephrol. Hypertens. 12 (1), 51-55. (Pubitemid 36092315)
45. Nguyen, G., Delarue, F., Berrou, J., Rondeau, E., Sraer, J.D., 1996. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kid Intl. 50, 1897-1903. (Pubitemid 26417532)
46. Nguyen, G., Delarue, F., Burckle, C., Bouzhir, L., Giller, T., Sraer, J.D., 2002. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427. (Pubitemid 34596167)
47. Nyathani, H.K., Srirangam, P., Jinugu, V.S., 2011. Renoprotective effects of combined aliskiren and valsartan in diabetic nephropathy in rats. Int. J. Pharm. Sci. Rev. Res. 6 (2), 152-158.
48. O'Brien, E., Barton, J., Nussberger, J., Mulcahy, D., Jensen, C., Dicker, P., Stanton, A.,2007. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin- converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertens. 49, 276-284. (Pubitemid 46143002)
49. Oparil, S., Yarows, S.A., Patel, S., Fang, H., Zhang, J., Satlin, A., 2007. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221-229. (Pubitemid 47069535)
50. Parving, H.H., Persson, F., Lewis, J.B., Lewis, E.J., Hollenberg, N.K. AVOID study Investigators, 2008. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446. (Pubitemid 351793017)
51. Perrone, R.D., Madias, N.E., Levey, A.S., 1992. Serum creatinine as an index of renal function. New insights into an old concept. Clin. Chem. 38, 1933.
52. Pilz, B., Shagdarsuren, E., Wellner, M., Fiebeler, A., Dechend, R., Gratze, P., Meiner, S., Feldman, D.L., Webb, R.L., Garrelds, I.M., Danser, J., Luft, F.C., Muller, D.N., 2005. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46, 569-576. (Pubitemid 41376839)
53. Price, D.A., Porter, L.E., Gordon, M., Fisher, N.D., De'Oliveira, J.M., Laffel, L.M., Passan, D.R., Williams, G.H., Hollenberg, N.K., 1999. The paradox of the low-renin state in diabetic nephropathy. J. Am. Soc. Nephrol. 10, 2382-2391. (Pubitemid 29501472)
54. Pugsley, M.K., 2005. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc. West. Pharmacol. Soc. 48, 35-38. (Pubitemid 43053796)
55. Remuzzi, G., Benigni, A., Remuzzi, A., 2006. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288-296. (Pubitemid 43228342)
56. Roy, S., Sen, C.K., Kobuchi, H., Packer, L., 1998. Antioxidant regulation of phorbol ester-induced adhesion of human Jurkat T-cells to endothelial cells. Free Radic. Biol. Med. 25 (2), 229-241. (Pubitemid 28293159)
57. Scherer, P.E., Bickel, P.E., Kotler, M., Lodish, H.F., 1998. Cloning of cell-specific secreted and surface proteins by subtractive antibody screening. Nat. Biotechnol. 16, 581-586. (Pubitemid 28269819)
58. Schiffrin, E.L., Lipman, M.L., Mann, J.F., 2007. Chronic kidney disease: effects on the cardiovascular system. Circulation 116 (1), 85-97. (Pubitemid 47016250)
59. Skeggs Jr., L.T., Kahn, J.R., Lentz, K., Shumway, N.P., et al., 1957. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J. Exp. Med. 106, 439-453.
60. Sonta, T., Inoguchi, T., Matsumoto, S., Yasukawa, K., Inuo, M., Tsubouchi, H., Sonoda, N., Kobayashi, K., Utsumi, H., Nawata, H., 2005. In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker. Biochem. Biophys. Res. Commun. 330, 415-422. (Pubitemid 40417661)
61. Stanton, A., Jensen, C., Nussberger, J., O'Brien, E., 2003. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42, 1137-1143. (Pubitemid 37549068)
62. Stergren, 2007. Renin-angiotensin-system blockade in the prevention of diabetes. Diabetes Res. Clin. Pract. 76S, S13-S21.
63. Stucchi, P., Cano, V., Ruiz-Gayo, M., Fernández-Alfonso, M.S., 2009. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. British J. Pharmacol. 158, 771-778.
64. Tenstad, O., Roald, A.B., Grubb, A., Aukland, K., 1996. Renal handing of radiolabelled human cystatin C in the rat. Scand. J. Clin. Lab. Invest. 56, 409-414. (Pubitemid 26266006)
65. Van de Wal, R.M., van Veldhuisen, D.J., van Gilst, W.H., Voors, A.A., 2005. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J. 26 (22), 2361-2367. (Pubitemid 41552963)
66. Villamil, A., Chrysant, S.G., Calhoun, D., Schober, B., Hsu, H., Matrisciano- Dimichino, L., Zhang, J., 2007. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 25, 217-226. (Pubitemid 44885684)
67. Weir, G.C., Clore, E.E., Zma-Chinsky, C.J., Bonnier-weir, S., 1981. Islet secretion in new experimental model of non-insulin dependant diabetes. Diab. Metabol. Rev. 30, 590-594.
68. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al., 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295. (Pubitemid 35373562)
69. Yoshihiko, H., Takuya, I., Kaoru, Y., Nobuo, K., 2007. Effects of Hachimi-jio-gan (Ba- Wei-Di-Huang-Wan) on hyperglycemia in streptozotocin- induced diabetic rats. Biol. Pharm. Bull. 30 (5), 1015-1020.